Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro (Q73710607)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Jorma Hinkula

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Sergey Pertel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

V I Grishkovets

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Y L Krivorutchenko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Y S Krivoshein

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

E Ljungdahl-Ståhle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A E Zemlyakov

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

B Wahren

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 August 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

12-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

1479-1486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

Adjuvants--a balance between toxicity and adjuvanticity

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Status of immune-based therapies in HIV infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Development of a vaccine for the prevention of AIDS, a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)].

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Cytokine-containing liposomes as adjuvants for HIV subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide analog

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Nef and Gag synthetic peptide priming of antibody responses to HIV type 1 antigens in mice and primates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Muramyl peptides. Variation of somnogenic activity with structure

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Adjuvanticity and ISCOM formation by structurally diverse saponins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

Selection of a muramyl peptide based on its lack of activation of nuclear factor-kappa B as a potential adjuvant for AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2897%2900065-0

7 January 2021

10.1016/S0264-410X(97)00065-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9302764%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference